Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia : Data from 95 consecutive patients treated in a compassionate use program. A study from the swedish chronic lymphocytic leukemia group
Ibrutinib, a Bruton’s tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine healthcare are commonly observed in oncology. Herein we report real-world results for 95 poor prognosis Swedish patients treated with ibrutinib in a compassionate use program. Ninety-five consecutive patients (
